Last reviewed · How we verify
ABX464
ABX464 is a small molecule that modulates RNA splicing to promote the production of anti-inflammatory isoforms of proteins involved in immune regulation.
ABX464 is a small molecule that modulates RNA splicing to promote the production of anti-inflammatory isoforms of proteins involved in immune regulation. Used for Inflammatory bowel disease (Crohn's disease), HIV infection.
At a glance
| Generic name | ABX464 |
|---|---|
| Also known as | Obefazimod |
| Sponsor | Abivax S.A. |
| Drug class | RNA splicing modulator |
| Target | RNA splicing machinery (non-specific modulator) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
ABX464 acts as an RNA splicing modulator that selectively enhances the production of anti-inflammatory protein variants, particularly affecting immune response pathways. By shifting the balance toward anti-inflammatory isoforms, it reduces excessive immune activation and inflammation. This mechanism is designed to restore immune homeostasis in inflammatory and infectious diseases.
Approved indications
- Inflammatory bowel disease (Crohn's disease)
- HIV infection
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Headache
Key clinical trials
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (PHASE2)
- ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 (PHASE2, PHASE3)
- Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis (PHASE2)
- ABTECT - Maintenance (PHASE3)
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 (PHASE3)
- ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 (PHASE3)
- Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis (PHASE2)
- Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABX464 CI brief — competitive landscape report
- ABX464 updates RSS · CI watch RSS
- Abivax S.A. portfolio CI